JPRN-UMIN000024922
Completed
未知
Comparative trial of SGLT2-inhibitor (Canagliflozin) and sulfonylurea (Glimepiride) for patients with DM - Comparative trial of SGLT2-inhibitor (Canagliflozin) and sulfonylurea (Glimepiride) for patients with DM
ConditionsDiabetes mellitus type 2
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diabetes mellitus type 2
- Sponsor
- Sekino Hospital
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who were deemed not appropriate to participate in this study by doctor
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Effect of SGLT2 inhibitor, canagliflozin, for the size of lipid particlesType 2 diabetesJPRN-UMIN000020027Tokyo Medical and Dental University Department of Medical Genetics / Gerontorgy30
Recruiting
Phase 3
Prospective Comparison of SGLT-2 inhibitor, Luseogliflozin, versus GLP-1 Receptor Agonist,Dulaglutide, on Regression of Coronary Atherosclerosis with Type 2 Diabetes MellitusJPRN-jRCTs031180408Aso Yoshimasa200
Recruiting
Not Applicable
Prospective Comparison of SGLT-2 inhibitor, Luseogliflozin,versus GLP-1 Receptor Agonist,Dulaglutide, on Regression of Coronary Atherosclerosis with Type 2 Diabetes Mellitus who have Undergone Percutaneous Coronary Intervention: Open-label Randomized Parallel-group TrialType 2 diabetes who have undergone percutaneous coronary interventionJPRN-UMIN000026630Dokkyo medical university hospital200
Not yet recruiting
Not Applicable
Effect of SGLT2 inhibitor, Dapagliflozin combined with or without metformin on body composition in patients with type 2 diabetestype 2 diabetes mellitusJPRN-UMIN000030446St. Marianna University School of Medicine54
Active, not recruiting
Phase 1
Short-term effects of the substance dapagliflozin on the increase of blood sugar concentrations after meal and insulinsensitivity in type 1 diabetic patients.effects of Dapagliflozin on postprandial glucose excursion and fasting glucose homeostasisTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2014-001441-24-ATMedical University Innsbruck12